Zydus Lifesciences gets USFDA EIR for Moraiya facility
Advertisement
Ahmedabad: Global Lifesciences company, Zydus Lifesciences Ltd., today announced the receipt of an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its formulations manufacturing facility in Moraiya, near Ahmedabad, India.
The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI).
Voluntary Action Indicated (VAI) means objectionable conditions or practices were found but the agency is not prepared to take or recommend any administrative or regulatory action.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.